Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 403

1.

Bone-Targeting Radiopharmaceuticals as Monotherapy or Combined With Chemotherapy in Patients With Castration-Resistant Prostate Cancer Metastatic to Bone.

Bouman-Wammes EW, de Klerk JMH, Bloemendal HJ, Van Dodewaard-de Jong JM, Lange R, Ter Heine R, Verheul HMW, Van den Eertwegh AJM.

Clin Genitourin Cancer. 2018 Nov 17. pii: S1558-7673(18)30099-5. doi: 10.1016/j.clgc.2018.11.014. [Epub ahead of print] Review.

PMID:
30555024
2.

The predictive value of cumulative toxicity for quality of life in patients with metastatic colorectal cancer during first-line palliative chemotherapy.

Schuurhuizen CS, Verheul HM, Braamse AM, Buffart LM, Bloemendal HJ, Dekker J, Konings IR.

Cancer Manag Res. 2018 Aug 29;10:3015-3021. doi: 10.2147/CMAR.S166468. eCollection 2018.

3.

Four-year effects of exercise on fatigue and physical activity in patients with cancer.

Witlox L, Hiensch AE, Velthuis MJ, Steins Bisschop CN, Los M, Erdkamp FLG, Bloemendal HJ, Verhaar M, Ten Bokkel Huinink D, van der Wall E, Peeters PHM, May AM.

BMC Med. 2018 Jun 8;16(1):86. doi: 10.1186/s12916-018-1075-x.

4.

Tolerability, Safety, and Outcomes of Neoadjuvant Chemoradiotherapy With Capecitabine for Patients Aged ≥ 70 Years With Locally Advanced Rectal Cancer.

Jacobs L, van der Vlies E, Ten Bokkel Huinink D, Bloemendal H, Intven M, Smits AB, Weusten BLAM, Siersema PD, van Lelyveld N, Los M.

Clin Colorectal Cancer. 2018 Sep;17(3):179-186. doi: 10.1016/j.clcc.2018.03.004. Epub 2018 Mar 8.

PMID:
29661620
5.

Phase I study of combined indomethacin and platinum-based chemotherapy to reduce platinum-induced fatty acids.

van der Velden DL, Cirkel GA, Houthuijzen JM, van Werkhoven E, Roodhart JML, Daenen LGM, Kaing S, Gerrits J, Verhoeven-Duif NM, Grootscholten C, Boot H, Sessa C, Bloemendal HJ, De Vos FY, Voest EE.

Cancer Chemother Pharmacol. 2018 May;81(5):911-921. doi: 10.1007/s00280-018-3563-2. Epub 2018 Mar 24.

PMID:
29574584
6.

Cost of illness of metastatic prostate cancer: a perspective of costs for new treatment options in The Netherlands.

Ter Heine R, Frederix GW, Geenen JW, Hövels AM, van Vulpen M, Kooistra A, De Klerk JM, Bloemendal HJ.

J Comp Eff Res. 2017 Oct;6(7):575-581. doi: 10.2217/cer-2017-0026. Epub 2017 Sep 13.

PMID:
29091013
7.

Differences in Trial and Real-world Populations in the Dutch Castration-resistant Prostate Cancer Registry.

Westgeest HM, Uyl-de Groot CA, van Moorselaar RJA, de Wit R, van den Bergh ACM, Coenen JLLM, Beerlage HP, Hendriks MP, Bos MMEM, van den Berg P, van de Wouw AJ, Spermon R, Boerma MO, Geenen MM, Tick LW, Polee MB, Bloemendal HJ, Cordia I, Peters FPJ, de Vos AI, van den Bosch J, van den Eertwegh AJM, Gerritsen WR.

Eur Urol Focus. 2018 Sep;4(5):694-701. doi: 10.1016/j.euf.2016.09.008. Epub 2016 Oct 13.

PMID:
28753794
8.

Nationwide comprehensive gastro-intestinal cancer cohorts: the 3P initiative.

Coebergh van den Braak RRJ, van Rijssen LB, van Kleef JJ, Vink GR, Berbee M, van Berge Henegouwen MI, Bloemendal HJ, Bruno MJ, Burgmans MC, Busch ORC, Coene PPLO, Coupé VMH, Dekker JWT, van Eijck CHJ, Elferink MAG, Erdkamp FLG, van Grevenstein WMU, de Groot JWB, van Grieken NCT, de Hingh IHJT, Hulshof MCCM, Ijzermans JNM, Kwakkenbos L, Lemmens VEPP, Los M, Meijer GA, Molenaar IQ, Nieuwenhuijzen GAP, de Noo ME, van de Poll-Franse LV, Punt CJA, Rietbroek RC, Roeloffzen WWH, Rozema T, Ruurda JP, van Sandick JW, Schiphorst AHW, Schipper H, Siersema PD, Slingerland M, Sommeijer DW, Spaander MCW, Sprangers MAG, Stockmann HBAC, Strijker M, van Tienhoven G, Timmermans LM, Tjin-A-Ton MLR, van der Velden AMT, Verhaar MJ, Verkooijen HM, Vles WJ, de Vos-Geelen JMPGM, Wilmink JW, Zimmerman DDE, van Oijen MGH, Koopman M, Besselink MGH, van Laarhoven HWM; Dutch Pancreatic Cancer Group, Dutch Upper GI Cancer Group and PLCRC working group.

Acta Oncol. 2018 Feb;57(2):195-202. doi: 10.1080/0284186X.2017.1346381. Epub 2017 Jul 19.

PMID:
28723307
9.

Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial.

Bamias A, Gibbs E, Khoon Lee C, Davies L, Dimopoulos M, Zagouri F, Veillard AS, Kosse J, Santaballa A, Mirza MR, Tabaro G, Vergote I, Bloemendal H, Lykka M, Floquet A, Gebski V, Pujade-Lauraine E.

Ann Oncol. 2017 Aug 1;28(8):1842-1848. doi: 10.1093/annonc/mdx228.

PMID:
28481967
10.

Imatinib treatment of poor prognosis mesenchymal-type primary colon cancer: a proof-of-concept study in the preoperative window period (ImPACCT).

Ubink I, Bloemendal HJ, Elias SG, Brink MA, Schwartz MP, Holierhoek YCW, Verheijen PM, Boerman AW, Mathijssen RHJ, de Leng WWJ, de Weger RA, van Grevenstein WMU, Koopman M, Lolkema MP, Kranenburg O, Borel Rinkes IHM.

BMC Cancer. 2017 Apr 19;17(1):282. doi: 10.1186/s12885-017-3264-y.

11.

A randomised, phase II study of repeated rhenium-188-HEDP combined with docetaxel and prednisone versus docetaxel and prednisone alone in castration-resistant prostate cancer (CRPC) metastatic to bone; the Taxium II trial.

van Dodewaard-de Jong JM, de Klerk JMH, Bloemendal HJ, Oprea-Lager DE, Hoekstra OS, van den Berg HP, Los M, Beeker A, Jonker MA, O'Sullivan JM, Verheul HMW, van den Eertwegh AJM.

Eur J Nucl Med Mol Imaging. 2017 Aug;44(8):1319-1327. doi: 10.1007/s00259-017-3673-9. Epub 2017 Apr 18.

PMID:
28421240
12.

Towards better dose individualisation: metabolic phenotyping to predict cabazitaxel pharmacokinetics in men with prostate cancer.

Janssen A, Verkleij CPM, van der Vlist A, Mathijssen RHJ, Bloemendal HJ, Ter Heine R.

Br J Cancer. 2017 May 9;116(10):1312-1317. doi: 10.1038/bjc.2017.91. Epub 2017 Apr 11.

13.

Cost-effectiveness analysis of an 18-week exercise programme for patients with breast and colon cancer undergoing adjuvant chemotherapy: the randomised PACT study.

May AM, Bosch MJ, Velthuis MJ, van der Wall E, Steins Bisschop CN, Los M, Erdkamp F, Bloemendal HJ, de Roos MA, Verhaar M, Ten Bokkel Huinink D, Peeters PH, de Wit GA.

BMJ Open. 2017 Mar 6;7(3):e012187. doi: 10.1136/bmjopen-2016-012187.

14.

A Phase 1 Trial of Cabazitaxel Combined With 188Re-Hydroxyethylidene Diphosphonate in Patients With Metastatic Castration-Resistant Prostate Cancer Who Progressed on or After a Docetaxel-Containing Treatment: The ReCab Trial.

van Dodewaard-de Jong JM, Bouman-Wammes EW, Bloemendal HJ, Verheul HMW, de Klerk JMH, van den Eertwegh AJM.

Clin Nucl Med. 2017 Jun;42(6):415-420. doi: 10.1097/RLU.0000000000001604.

PMID:
28263212
15.

Cytotoxic Effects of the Therapeutic Radionuclide Rhenium-188 Combined with Taxanes in Human Prostate Carcinoma Cell Lines.

Lange R, ter Heine R, van Wieringen WN, Tromp AM, Paap M, Bloemendal HJ, de Klerk JM, Hendrikse NH, Geldof AA.

Cancer Biother Radiopharm. 2017 Feb;32(1):16-23. doi: 10.1089/cbr.2016.2129. Epub 2017 Jan 24.

PMID:
28118029
16.

Erratum to "Pharmaceutical and clinical development of phosphonate-based radiopharmaceuticals for the targeted treatment of bone metastases" [Bone 91 (2016) 159-179].

Lange R, Ter Heine R, Knapp RF, de Klerk JMH, Bloemendal HJ, Hendrikse HN.

Bone. 2017 Dec;105:315. doi: 10.1016/j.bone.2016.11.023. Epub 2016 Nov 30. No abstract available.

PMID:
27914925
17.

Pharmaceutical and clinical development of phosphonate-based radiopharmaceuticals for the targeted treatment of bone metastases.

Lange R, Ter Heine R, Knapp RF, de Klerk JM, Bloemendal HJ, Hendrikse NH.

Bone. 2016 Oct;91:159-79. doi: 10.1016/j.bone.2016.08.002. Epub 2016 Aug 2. Review. Erratum in: Bone. 2017 Dec;105:315.

PMID:
27496068
18.

Treatment of painful bone metastases in prostate and breast cancer patients with the therapeutic radiopharmaceutical rhenium-188-HEDP. Clinical benefit in a real-world study.

Lange R, Overbeek F, de Klerk JM, Pasker-de Jong PC, van den Berk AM, Ter Heine R, Rodenburg CJ, Kooistra A, Hendrikse NH, Bloemendal HJ.

Nuklearmedizin. 2016 Sep 26;55(5):188-95. doi: 10.3413/Nukmed-0828-16-05. Epub 2016 Jul 22.

PMID:
27443809
19.

Applying quality by design principles to the small-scale preparation of the bone-targeting therapeutic radiopharmaceutical rhenium-188-HEDP.

Lange R, Ter Heine R, van der Gronde T, Selles S, de Klerk J, Bloemendal H, Hendrikse H.

Eur J Pharm Sci. 2016 Jul 30;90:96-101. doi: 10.1016/j.ejps.2016.01.008. Epub 2016 Jan 7.

PMID:
26772897
20.

Effects of an Exercise Program in Colon Cancer Patients undergoing Chemotherapy.

Van Vulpen JK, Velthuis MJ, Steins Bisschop CN, Travier N, Van Den Buijs BJ, Backx FJ, Los M, Erdkamp FL, Bloemendal HJ, Koopman M, De Roos MA, Verhaar MJ, Ten Bokkel-Huinink D, Van Der Wall E, Peeters PH, May AM.

Med Sci Sports Exerc. 2016 May;48(5):767-75. doi: 10.1249/MSS.0000000000000855.

PMID:
26694846
21.

Radiopharmaceuticals for Palliation of Bone Pain in Patients with Castration-resistant Prostate Cancer Metastatic to Bone: A Systematic Review.

Jong JM, Oprea-Lager DE, Hooft L, de Klerk JM, Bloemendal HJ, Verheul HM, Hoekstra OS, van den Eertwegh AJ.

Eur Urol. 2016 Sep;70(3):416-26. doi: 10.1016/j.eururo.2015.09.005. Epub 2015 Sep 19. Review.

PMID:
26391636
22.

Effects of an 18-week exercise programme started early during breast cancer treatment: a randomised controlled trial.

Travier N, Velthuis MJ, Steins Bisschop CN, van den Buijs B, Monninkhof EM, Backx F, Los M, Erdkamp F, Bloemendal HJ, Rodenhuis C, de Roos MA, Verhaar M, ten Bokkel Huinink D, van der Wall E, Peeters PH, May AM.

BMC Med. 2015 Jun 8;13:121. doi: 10.1186/s12916-015-0362-z.

23.

New Treatment Options for Patients With Metastatic Prostate Cancer: What Is The Optimal Sequence?

van Dodewaard-de Jong JM, Verheul HMW, Bloemendal HJ, de Klerk JMH, Carducci MA, van den Eertwegh AJM.

Clin Genitourin Cancer. 2015 Aug;13(4):271-279. doi: 10.1016/j.clgc.2015.01.008. Epub 2015 Jan 21. Review.

PMID:
25704270
24.

Drug composition matters: the influence of carrier concentration on the radiochemical purity, hydroxyapatite affinity and in-vivo bone accumulation of the therapeutic radiopharmaceutical 188Rhenium-HEDP.

Lange R, de Klerk JMH, Bloemendal HJ, Ramakers RM, Beekman FJ, van der Westerlaken MML, Hendrikse NH, Ter Heine R.

Nucl Med Biol. 2015 May;42(5):465-469. doi: 10.1016/j.nucmedbio.2015.01.007. Epub 2015 Jan 22.

PMID:
25662844
25.

Metastatic Prostate Cancer and Skeletal Related Events, a Cost of Illness Study.

Geenen JW, Heine Ter R, Frederix GW, Hövels A, Vulpen van M, Kooistra A, Klerk de JM, Bloemendal HJ.

Value Health. 2014 Nov;17(7):A626. doi: 10.1016/j.jval.2014.08.2229. Epub 2014 Oct 26. No abstract available.

26.

Bench to bedside development of GMP grade Rhenium-188-HEDP, a radiopharmaceutical for targeted treatment of painful bone metastases.

ter Heine R, Lange R, Breukels OB, Bloemendal HJ, Rummenie RG, Wakker AM, de Graaf H, Beekman FJ, van der Westerlaken MM, Malingré MM, Wielders JP, van den Berg L, Hendrikse NH, de Klerk JM.

Int J Pharm. 2014 Apr 25;465(1-2):317-24. doi: 10.1016/j.ijpharm.2014.01.034. Epub 2014 Feb 19.

PMID:
24560635
27.

Severe hypertriglyceridaemia associated with the use of capecitabine.

Polinder-Bos HA, Kok EE, van de Wiel A, Spiering W, Wielders JP, Bloemendal HJ.

Neth J Med. 2012 Mar;70(2):104. No abstract available.

28.

A phase I study of combined docetaxel and repeated high activity 186Re-HEDP in castration-resistant prostate cancer (CRPC) metastatic to bone (the TAXIUM trial).

van Dodewaard-de Jong JM, de Klerk JM, Bloemendal HJ, van Bezooijen BP, de Haas MJ, Wilson RH, O'Sullivan JM.

Eur J Nucl Med Mol Imaging. 2011 Nov;38(11):1990-8. doi: 10.1007/s00259-011-1883-0. Epub 2011 Jul 27.

PMID:
21792569
29.

Lapatinib: clinical benefit in patients with HER 2-positive advanced breast cancer.

Kroep JR, Linn SC, Boven E, Bloemendal HJ, Baas J, Mandjes IA, van den Bosch J, Smit WM, de Graaf H, Schröder CP, Vermeulen GJ, Hop WC, Nortier JW.

Neth J Med. 2010 Sep;68(9):371-6.

30.

Subtoxic oxidative stress induces senescence in retinal pigment epithelial cells via TGF-beta release.

Yu AL, Fuchshofer R, Kook D, Kampik A, Bloemendal H, Welge-Lüssen U.

Invest Ophthalmol Vis Sci. 2009 Feb;50(2):926-35. doi: 10.1167/iovs.07-1003.

PMID:
19171648
31.

Reactivation of optic nerve head astrocytes by TGF-beta2 and H2O2 is accompanied by increased Hsp32 and Hsp47 expression.

Yu AL, Moriniere J, Birke M, Neumann C, Fuchshofer R, Kampik A, Bloemendal H, Welge-Lussen U.

Invest Ophthalmol Vis Sci. 2009 Apr;50(4):1707-17. doi: 10.1167/iovs.08-1961. Epub 2008 Oct 24.

PMID:
18952926
32.

Oxidative stress and TGF-beta2 increase heat shock protein 27 expression in human optic nerve head astrocytes.

Yu AL, Fuchshofer R, Birke M, Kampik A, Bloemendal H, Welge-Lüssen U.

Invest Ophthalmol Vis Sci. 2008 Dec;49(12):5403-11. doi: 10.1167/iovs.07-1478. Epub 2008 Jun 14.

PMID:
18552392
33.

Tissue transglutaminase catalyzes the deamidation of glutamines in lens betaB(2)- and betaB(3)-crystallins.

Boros S, Wilmarth PA, Kamps B, de Jong WW, Bloemendal H, Lampi K, Boelens WC.

Exp Eye Res. 2008 Feb;86(2):383-93. doi: 10.1016/j.exer.2007.11.011. Epub 2007 Nov 29.

PMID:
18184610
34.

Hypoxia/reoxygenation and TGF-beta increase alphaB-crystallin expression in human optic nerve head astrocytes.

Yu AL, Fuchshofer R, Birke M, Priglinger SG, Eibl KH, Kampik A, Bloemendal H, Welge-Lussen U.

Exp Eye Res. 2007 Apr;84(4):694-706. Epub 2006 Dec 15.

PMID:
17261280
35.

Structural and immunocytochemical alterations in eye lens fiber cells from Cx46 and Cx50 knockout mice.

Dunia I, Cibert C, Gong X, Xia CH, Recouvreur M, Levy E, Kumar N, Bloemendal H, Benedetti EL.

Eur J Cell Biol. 2006 Aug;85(8):729-52. Epub 2006 Jun 5.

PMID:
16740340
36.

Ageing and vision: structure, stability and function of lens crystallins.

Bloemendal H, de Jong W, Jaenicke R, Lubsen NH, Slingsby C, Tardieu A.

Prog Biophys Mol Biol. 2004 Nov;86(3):407-85. Review.

PMID:
15302206
37.

Activated vitronectin as a target for anticancer therapy with human antibodies.

Bloemendal HJ, de Boer HC, Koop EA, van Dongen AJ, Goldschmeding R, Landman WJ, Logtenberg T, Gebbink MF, Voest EE.

Cancer Immunol Immunother. 2004 Sep;53(9):799-808. Epub 2004 Jun 10.

PMID:
15197494
38.

Dr. Josef Steiner Cancer Research Prize 2003 to EJCB Board Member María Blasco.

Bloemendal H, Gebauer D, Jahn R, Schliwa M, Werner S.

Eur J Cell Biol. 2004 Feb;83(1):1-2. No abstract available.

PMID:
15085949
39.

Fibrin-incorporated vitronectin is involved in platelet adhesion and thrombus formation through homotypic interactions with platelet-associated vitronectin.

Wu YP, Bloemendal HJ, Voest EE, Logtenberg T, de Groot PG, Gebbink MF, de Boer HC.

Blood. 2004 Aug 15;104(4):1034-41. Epub 2004 Apr 6.

40.

Nuclear staining for the small heat shock protein alphaB-crystallin colocalizes with splicing factor SC35.

van Rijk AE, Stege GJ, Bennink EJ, May A, Bloemendal H.

Eur J Cell Biol. 2003 Jul;82(7):361-8.

PMID:
12924631
41.

Molecular mechanisms of exon shuffling: illegitimate recombination.

van Rijk A, Bloemendal H.

Genetica. 2003 Jul;118(2-3):245-9. Review.

PMID:
12868613
42.

Pathogenesis of axonal dystrophy and demyelination in alphaA-crystallin-expressing transgenic mice.

Van Rijk AF, Sweers MA, Merkx GF, Lammens M, Bloemendal H.

Int J Exp Pathol. 2003 Apr;84(2):91-9.

43.

[Cerebral infarction and myocardial infarction due to cisplatin-containing chemotherapy].

Brouha ME, Bloemendal HJ, Kappelle LJ, Winter JB.

Ned Tijdschr Geneeskd. 2003 Mar 8;147(10):457-60. Dutch. Erratum in: Ned Tijdschr Geneeskd. 2003 Dec 27;147(52):2612.

PMID:
12666519
44.

Retinal pigment epithelium is protected against apoptosis by alphaB-crystallin.

Alge CS, Priglinger SG, Neubauer AS, Kampik A, Zillig M, Bloemendal H, Welge-Lussen U.

Invest Ophthalmol Vis Sci. 2002 Nov;43(11):3575-82.

PMID:
12407170
45.

Sodium dodecyl sulfate-freeze-fracture immunolabeling of gap junctions.

Dunia I, Recouvreur M, Nicolas P, Kumar NM, Bloemendal H, Benedetti EL.

Methods Mol Biol. 2001;154:33-55. No abstract available.

PMID:
11218657
46.

Transforming growth factor-beta: a growth factor inducing alpha B-crystallin expression in ciliary muscle cells.

Welge-Lüssen U, Bloemendal H, Lütjen-Drecoll E.

Graefes Arch Clin Exp Ophthalmol. 2000 Dec;238(12):993-7.

PMID:
11196363
47.

UV-A-related alterations of young and adult lens water-insoluble alpha-crystallin, plasma membranous and cytoskeletal proteins.

Weinreb O, Dovrat A, Dunia I, Benedetti EL, Bloemendal H.

Eur J Biochem. 2001 Feb;268(3):536-43.

48.

In vitro filament-like formation upon interaction between lens alpha-crystallin and betaL-crystallin promoted by stress.

Weinreb O, van Rijk AF, Dovrat A, Bloemendal H.

Invest Ophthalmol Vis Sci. 2000 Nov;41(12):3893-7.

PMID:
11053291
49.

AlphaB-crystallin in lacrimal gland duct and tears.

May CA, Welge-Lüssen U, Jünemann A, Bloemendal H, Lütjen-Drecoll E.

Curr Eye Res. 2000 Jul;21(1):588-94.

PMID:
11035541
50.

Characteristics of super alphaA-crystallin, a product of in vitro exon shuffling.

van Rijk AF, van den Hurk MJ, Renkema W, Boelens WC, de Jong WW, Bloemendal H.

FEBS Lett. 2000 Sep 1;480(2-3):79-83.

Supplemental Content

Loading ...
Support Center